Lord, Abbett & Co. LLC Nuvalent, Inc. Transaction History
Lord, Abbett & Co. LLC
- $30.6 Billion
- Q2 2024
A detailed history of Lord, Abbett & Co. LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Lord, Abbett & Co. LLC holds 238,205 shares of NUVL stock, worth $21.3 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
238,205
Previous 452,192
47.32%
Holding current value
$21.3 Million
Previous $34 Million
46.78%
% of portfolio
0.06%
Previous 0.11%
Shares
6 transactions
Others Institutions Holding NUVL
# of Institutions
180Shares Held
56.6MCall Options Held
527KPut Options Held
131K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.78 Billion31.83% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.57MShares$408 Million14.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.78MShares$337 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$270 Million0.01% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.7MShares$241 Million41.86% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.83B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...